{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T23:01:06Z","timestamp":1772319666172,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005689","name":"G\u00f6teborgs L\u00e4kares\u00e4llskap","doi-asserted-by":"publisher","award":["GLS-413241"],"award-info":[{"award-number":["GLS-413241"]}],"id":[{"id":"10.13039\/501100005689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005689","name":"G\u00f6teborgs L\u00e4kares\u00e4llskap","doi-asserted-by":"publisher","award":["GLS-330101"],"award-info":[{"award-number":["GLS-330101"]}],"id":[{"id":"10.13039\/501100005689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"Region Vastra Gotaland","doi-asserted-by":"publisher","award":["VGFOUREG-151311"],"award-info":[{"award-number":["VGFOUREG-151311"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"Region Vastra Gotaland","doi-asserted-by":"publisher","award":["VGFOUREG-650341"],"award-info":[{"award-number":["VGFOUREG-650341"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"Region Vastra Gotaland","doi-asserted-by":"publisher","award":["VGFOUREG-467491"],"award-info":[{"award-number":["VGFOUREG-467491"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005760","name":"G\u00f6teborgs Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005754","name":"Sahlgrenska Universitetssjukhuset","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eprac.2024.12.007","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T01:54:51Z","timestamp":1733968491000},"page":"447-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab Treatment as Second-Line Therapy in Glucocorticoid Nonresponsive Graves' Orbitopathy: A Nonrandomized, Controlled, Interventional Study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-0772","authenticated-orcid":false,"given":"Sofia","family":"Manousou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin","family":"Ekdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge","family":"Malmgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Filipsson Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eprac.2024.12.007_bib1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden","volume":"165","author":"Abraham-Nordling","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.007_bib2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.007_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11910-012-0256-9","article-title":"Thyroid eye disease: towards an evidence base for treatment in the 21st century","volume":"12","author":"Gillespie","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.007_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","article-title":"Graves' ophthalmopathy","volume":"360","author":"Bartalena","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.007_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"For the European Group on Graves' Orbitopathy (EUGOGO). Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"Wiersinga","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.007_bib6","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.007_bib7","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a Consensus statement by the American thyroid association and the European thyroid association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.007_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.007_bib9","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.007_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.007_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S2213-8587(18)30022-6","article-title":"Graves' orbitopathy: the ongoing search for new treatment strategies","volume":"6","author":"Dalm","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.007_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European thyroid association\/European group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.007_bib13","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.007_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.007_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/01676830903104611","article-title":"Rituximab in the treatment of thyroid eye disease: science fiction?","volume":"28","author":"Salvi","year":"2009","journal-title":"Orbit"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.007_bib16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.007_bib17","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","article-title":"Rituximab therapy for Graves' orbitopathy: lessons from randomized control trials","volume":"176","author":"Stan","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2024.12.007_bib19","doi-asserted-by":"crossref","first-page":"h3783","DOI":"10.1136\/bmj.h3783","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis","volume":"351","author":"Maraka","year":"2015","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.007_bib20","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s10067-017-3848-6","article-title":"Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies","volume":"36","author":"Einarsson","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.007_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy","volume":"18","author":"Bartalena","year":"2008","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.007_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2024.12.007_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clinbiochem.2020.08.007","article-title":"Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays","volume":"86","author":"Higgins","year":"2020","journal-title":"Clin Biochem"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.007_bib24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1530\/eje.0.1390575","article-title":"The one microgram adrenocorticotropin test in the assessment of hypothalamic-pituitary-adrenal function","volume":"139","author":"Ambrosi","year":"1998","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.007_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/EJE-09-0521","article-title":"Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO","volume":"162","author":"Watt","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2024.12.007_bib26","series-title":"A\u00a0Language and Environment for statistical Computing","year":"2023"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.007_bib27","first-page":"1","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J\u00a0Stat Software"},{"key":"10.1016\/j.eprac.2024.12.007_bib28","author":"Arel-Bundock"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.007_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12020-016-1136-x","article-title":"Natural history of Graves' orbitopathy after treatment","volume":"57","author":"Menconi","year":"2017","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.007_bib30","first-page":"473","article-title":"Studies on the occurrence of ophthalmopathy in Graves' disease","volume":"120","author":"Marcocci","year":"1989","journal-title":"Acta Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.007_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","article-title":"Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic","volume":"38","author":"Perros","year":"1993","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.007_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"Wiersinga","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.007_bib33","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/annrheumdis-2012-201758","article-title":"Smoking, rheumatoid factor status and responses to rituximab","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.007_bib34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/EJE-11-0055","article-title":"Quality of life in thyroid eye disease: impact of quality of care","volume":"164","author":"Estcourt","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.007_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1210\/jc.2012-3119","article-title":"Public health relevance of Graves' orbitopathy","volume":"98","author":"Ponto","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.007_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40618-017-0608-z","article-title":"For the European Group on Graves' Orbitopathy (EUGOGO). Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?","volume":"40","author":"Bartalena","year":"2017","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.007_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40265-018-1045-9","article-title":"Current and emerging treatment strategies for Graves' orbitopathy","volume":"79","author":"Genere","year":"2019","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2024.12.007_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000510700","article-title":"Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves' orbitopathy","volume":"9","author":"Bartalena","year":"2020","journal-title":"Eur Thyroid J"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.007_bib39","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"For the European Group on Graves' Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:57:56Z","timestamp":1762549076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1530891X24008632"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.007","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab Treatment as Second-Line Therapy in Glucocorticoid Nonresponsive Graves' Orbitopathy: A Nonrandomized, Controlled, Interventional Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}